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Abstract 
Background: Obesity, hypertension and prediabetes contribute greatly to coronary artery disease, heart failure and 
vascular events, and are the leading cause of mortality and morbidity in developed societies. Salt sensitivity exacer-
bates endothelial dysfunction. Herein, we investigated the effect of chronic glucagon like peptide-1 (GLP-1) receptor 
activation on the coronary microcirculation and cardiac remodeling in Zucker rats on a high-salt diet (6% NaCl).
Methods: Eight-week old Zucker lean (+/+) and obese (fa/fa) rats were treated with vehicle or liraglutide (LIRA) 
(0.1 mg/kg/day, s.c.) for 8 weeks. Systolic blood pressure (SBP) was measured using tail-cuff method in conscious 
rats. Myocardial function was assessed by echocardiography. Synchrotron contrast microangiography was then used 
to investigate coronary arterial vessel function (vessels 50–350 µm internal diameter) in vivo in anesthetized rats. 
Myocardial gene and protein expression levels of vasoactive factors, inflammatory, oxidative stress and remodeling 
markers were determined by real-time PCR and Western blotting.
Results: We found that in comparison to the vehicle-treated fa/fa rats, rats treated with LIRA showed significant 
improvement in acetylcholine-mediated vasodilation in the small arteries and arterioles (< 150 µm diameter). Neither 
soluble guanylyl cyclase or endothelial NO synthase (eNOS) mRNA levels or total eNOS protein expression in the 
myocardium were significantly altered by LIRA. However, LIRA downregulated Nox-1 mRNA (p = 0.030) and reduced 
ET-1 protein (p = 0.044) expression. LIRA significantly attenuated the expressions of proinflammatory and profibrotic 
associated biomarkers (NF-κB, CD68, IL-1β, TGF-β1, osteopontin) and nitrotyrosine in comparison to fa/fa-Veh rats, but 
did not attenuate perivascular fibrosis appreciably.
Conclusions: In a rat model of metabolic syndrome, chronic LIRA treatment improved the capacity for NO-mediated 
dilation throughout the coronary macro and microcirculations and partially normalized myocardial remodeling inde-
pendent of changes in body mass or blood glucose.
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Background
Obesity, hypertension and prediabetes contribute greatly 
to coronary artery disease, heart failure and vascular 
events, and thus the morbidity and mortality attrib-
utable to cardiovascular disease in modern societies. 
Overweight and obese adults in comparison to their 
non-obese counterparts, have a greater susceptibility for 
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subsequently developing diabetes mellitus and hyperten-
sion. Obesity leads to insulin resistance, vascular oxida-
tive stress, reduced availability of vascular nitric oxide 
(NO), endothelial and vasomotor dysfunction of the 
coronary microcirculation, which contributes greatly to 
the development of cardiovascular complications [1–3]. 
Numerous lines of evidence over recent decades from 
epidemiological and experimental studies have clearly 
established that high  Na+ intake not only contributes to 
elevated blood pressure, but also adverse cardiovascular 
remodeling, leading to the frequently reported higher 
incidence of cardiovascular events [4]. In common with 
obesity and diabetes, chronic high  Na+ intake has been 
shown in part to drive vascular and myocardial remod-
eling independent of hypertension. Chronic exposure 
to a high  Na+ diet was shown to impair aortic and mes-
enteric endothelial function in healthy Sprague–Daw-
ley rats independent of blood pressure alterations [5, 
6]. Similar findings have been observed in mice [7]. A 
combination of factors including vascular inflammation, 
an imbalance in redox state leading to excess oxidative 
stress, activation of the renin–angiotensin–aldosterone 
and sympathetic nervous systems are involved in the 
cardiovascular remodeling associated with chronic expo-
sure to high  Na+ intake, obesity and diabetes, and this is 
often shown to be compounded by the combination of 
these factors. Importantly, increased endothelial cell stiff-
ness, inflammation and oxidative stress, and the impair-
ment of endothelial function were shown to be mediated 
through upregulation of transforming growth factor beta 
(TGF-β1) following chronic high  Na+ intake [8]. Predia-
betic rats showed an exaggerated increase in peripheral 
perivascular inflammation and endothelial dysfunction 
to a high  Na+ diet (6% NaCl) compared to normal  Na+ 
diet and was associated with cardiac hypertrophy [9]. In 
that same study, angiotensin type 1 receptor blockade 
with valsartan was only partially effective in preventing 
the development of vascular damage but did not reduce 
cardiac hypertrophy induced by the high  Na+ diet.
Glucagon-like peptide-1 (GLP-1) agonists have been 
recently approved as new therapeutic agents for patients 
with diabetes, based on evidence that GLP-1 agonists 
can stimulate glucose dependent insulin secretion from 
the β-cells of pancreatic islets [10]. The LEADER clinical 
study [Liraglutide Effect and Action in Diabetes: Evalu-
ation of cardiovascular outcome Results] revealed that 
liraglutide (LIRA) treatment reduces mortality rates of 
cardiovascular events in diabetic patients [11]. LIRA 
treatment shown greater reductions in HbA1c in patients 
with cardiovascular events compared with placebo [12]. 
In addition, LIRA administration was more effective 
than metformin in suppressing vascular cell adhesion 
molecule (VCAM)-1 levels and reducing non-esterified 
free fatty acids recent-onset T2DM [13]. Indeed, previ-
ous studies have reported that GLP-1 agonist treatment 
has anti-inflammatory effects on peripheral vascular 
endothelial cells by increasing NO production and inhib-
iting cellular oxidative stress and apoptosis in diabetic 
animal models [14–16]. The chronic effects of GLP-1 
agonists on the coronary circulation are less clear. The 
GLP-1 agonist exenatide reduced coronary microves-
sel barrier dysfunction in  vivo in streptozotocin-treated 
rats and oxidative stress and apoptosis in endothelial 
cells cultured under high glucose conditions [17]. Sys-
temic infusion of GLP-1 increased cardiac microvascu-
lar blood volume and velocity in healthy human subjects 
[18]. Nonetheless, short term treatment with LIRA had 
no significant effect on coronary flow reserve or periph-
eral microvessel endothelial function in type 2 diabetes 
mellitus (T2DM) patients [19]. However, it was recently 
suggested that improved left ventricular (LV) function 
and reduced in arterial stiffness following 6  months of 
LIRA treatment is attributable to a reduction in oxidative 
stress in newly diagnosed T2DM patients [20]. Whether 
chronic LIRA treatment can prevent the progression of 
endothelial dysfunction in the coronary circulation and 
adverse myocardial remodeling associated with meta-
bolic syndrome has not been established. Recently, we 
showed that chronic LIRA treatment ameliorated the 
exacerbation of renal dysfunction and renal endothe-
lial dysfunction in the Zucker obese rat model of meta-
bolic syndrome compounded by high  Na+ diet intake 
[21]. Since high-salt intake has been shown to potenti-
ate cardiovascular inflammation and oxidative stress we 
hypothesized that chronic LIRA treatment of young adult 
Zucker obese rats on high-salt diet also prevents the 
development of inflammation, oxidative stress, coronary 
endothelial dysfunction and the pathological remodeling 
of the myocardium.
Materials and methods
Animal and experimental protocol
The study was approved by the National Cerebral and 
Cardiovascular Centre animal research committee 
(Approval number: 16079) and adhered for the “Guide 
for the Care and Use of Laboratory Animals” published 
by the US National Institutes of Health. Twenty-four 
male rats, Zucker lean (+/+, n = 12) and Zucker obese 
(fa/fa, n = 12) rats were purchased from SLC, Japan. 
Zucker +/+ and fa/fa rats were divided into two groups 
each to receive either saline or LIRA [0.1  mg/kg/day; 
2ML-4, Alzet, CA, USA] for 8 weeks starting at the age 
of 8 weeks. Rats were provided with ad libitum access to 
normal drinking water and fed with high-Na+ chow diet 
(6% NaCl w/v, Oriental Yeast Co., Ltd, Tokyo, Japan). 
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Liraglutide (VICTOZA) was purchased from Japan 
(Suzuken Co., Ltd., Tokyo, Japan).
Glomerular filtration rate (GFR) measurements in conscious 
rats
The non-invasive clearance (NIC) kidney device (Man-
nhein Pharma & Diagnostics, Mannheim, Germany) was 
used to measure the GFR transcutaneously in Zucker 
rats. The device was affixed on a depilated region of the 
back using a double-sided patch during brief anesthesia 
with 2% isoflurane soon after induction. Fluorescein iso-
thiocyanate (FITC)-sinistrin (7.5 mg/100 g bw, dissolved 
in saline; Fresenious Kabi, Linz, Austria) was adminis-
tered via tail-vein injection and the rats were then placed 
in a metabolic cage for 2  h before downloading the 
recorded signals from the NIC-kidney device [22].
Determination of renal function
Urinary levels of albumin, creatinine and albumin-cre-
atinine ratio were measured in a single rapid colorimet-
ric assay format using a Spectrum Diagnostic kit (Ref: 
06072885-6010A, Siemens Vantage 2000 analyzer, Erlan-
gen, Germany) according to the manufacturer’s proto-
col. Serum albumin and blood urea nitrogen (BUN) was 
measured by colorimetric qualitative analysis using com-
mercially available Fuji dry-chem slides (DRI-CHEM 
7000i, Fujifilm, Tokyo, Japan).
Blood pressure measurement and echocardiography
Systolic blood pressure (SBP) was measured every 
2-weeks in conscious animals by tail-cuff plethysmogra-
phy method (98A-L, Softron Corporation, Tokyo, Japan) 
in 36–37  °C pre-heated chambers for about 10–15  min 
following training sessions prior to recording. After 
8 weeks of high-salt diet, rats were subjected to transtho-
racic echocardiography during isoflurane anesthesia (2%) 
as previously described [23]. Briefly, intraventricular sep-
tal thickness at end-diastole (IVSd), intraventricular sep-
tal thickness at end-systole (IVDs), left ventricular (LV) 
dimension in the diastolic phase (LVDd), LV dimension 
in the systolic phase (LVDs), LV posterior wall thickness 
at end-diastole (LVPWd) and at end-systole (LVPWs) 
were measured with M-mode echocardiography utiliz-
ing a Vevo 2100 (Visual Sonics Inc., Ontario, Canada). LV 
long-axis fractional shortening (FS) and ejection fraction 
(EF) were calculated offline.
Surgical preparation and synchrotron radiation (SR) 
microangiography
Following high-salt diet treatment for 8  weeks, SR con-
trast microangiography was utilized to measure in  vivo 
coronary arterial vessel internal diameters (50–350  µm) 
and visualized vessel number in hypertensive insulin 
resistant +/+ and fa/fa rats (at 16  weeks of age) [21]. 
Rats were induced with isoflurane (4%) and anesthesia 
maintained (2%) throughout surgical preparation and 
the imaging experiment. All rats were artificially venti-
lated (Model MA-01746, Harward Apparatus, Holliston, 
USA) and a jugular vein was cannulated with polyethyl-
ene tubing (SP-31 Natsume Seisakusho Co., Ltd, Tokyo, 
Japan) for blood collection and renal function analyses, 
fasted blood glucose (FBG) measurement (500  μL) and 
drug infusion during the imaging protocol (Fig. 1b). Rec-
tal temperature was monitored and regulated at 36–37 °C 
using heating pad throughout the experimental proce-
dure. The right carotid artery was cannulated for high 
speed injection of contrast agent and a right femoral 
artery cannulated for recording of arterial pressure via 
pressure transducer (MLT0699, AD Instruments, NSW, 
Australia) to determine mean arterial pressure (MAP) 
and heart rate (HR). Contrast medium was injected as a 
small arterial bolus at 15 min intervals (0.3–0.4 mL bolus, 
Iomeron 350, Bracco-Eisai, Tokyo, Japan). The same 
imaging and high-speed shutter system as described in 
earlier studies was used here [24]. Images (1024 × 1024 
pixels) were stored in 10-bit format. In all images a 50 µm 
tungsten wire was included for calibration of vessel ID 
measurements. The input field of the SATICON X-ray 
detector system was 9.5  mm × 9.5  mm. Shutter open 
time was 0.8–1.0 ms. Monochromatic X-ray energy was 
adjusted to 33.2 keV, just above the iodine K-edge energy 
for maximal contrast. Coronary angiogram image analy-
sis was performed as previously described [18]. At the 
end of the imaging rats were killed by potassium chloride 
solution (2 mmol/kg) infusion under deep anesthesia and 
the myocardium was collected for further analysis.
SR microangiography protocol and rationale
Intraarterial injection of iodinated contrast was made 
during baseline conditions with a lactate infusion, 
then during a subsequent (1) infusion of acetylcho-
line (ACh, 5  µg/kg/min intravenous (i.v), (2) follow-
ing combined blockade of prostaglandin production 
with the cyclooxygenase (COX) inhibitor indometha-
cin (Indo, 10  mg/kg iv bolus) and (3) uncoupling of 
smooth muscle gap junctions with carbenoxolone 
administration (carbenox, 10  mg/kg iv bolus) follow-
ing a 10 min equilibration period. (4) We then assessed 
endothelium-dependent dilation after blockade with 
a repeat infusion of ACh (3.0  µg/kg/min) (Fig.  1b). 
Smooth muscle gap junctions are considered to be 
important for the distal transmission of dilation along 
vessels by conducted dilation, which is considered to 
be mediated by NO and endothelium derived hyper-
polarization factors (EDHF) including small and large 
Page 4 of 16Sukumaran et al. Cardiovasc Diabetol           (2020) 19:24 
conductance calcium-activated potassium channels 
and myoendothelial gap junctions [25]. Indo + car-
benox blockade was used in this study to inhibit radial 
dilation through prostanoids and myoendothelial gap 
junctions to determine if the reduced NO bioavail-
ability due to the metabolic syndrome impaired radial 
and conducted dilation within coronary vasculature. 
Changes in internal vessel diameter (ID) or caliber of 
the same vessels that were visualized in all treatment 
periods are considered in this study to be indicative of 
local (radial) dilatory function. On the other hand, a 
change in the number of angiographically visualized 
vessel segments during stimulation is used here as 
an index of a change in distal or conducted dilation. 
Therefore, we expected that any significant decrease 
in vessel ID or lack of change in ID during stimulation 
of the coronary vasculature with ACh infusion would 
indicate that there is underlying smooth muscle/
endothelial dysfunction respectively, involving impair-
ment of NO-mediated signaling. On the other hand, 
a reduction in newly visualized vessels during stimu-
lation or a lack of change in visualized vessel number 
would indicate that there is impairment in at least one 
of the mechanisms responsible for conduction of dis-
tal dilation and regulation of global perfusion (NO and 
EDHF).
Assessment of vessel internal diameter and visible vessel 
number
Quantitative measurements of vessel internal diameter 
(ID) was described as previously [19, 24] using ImageJ 
(version 1.48, NIH, Bethesda, USA). All angiograms were 
under went median filtering (2-pixel radius) before ves-
sel ID determination. Arterial vessels were categorized 
according to their branching order (1st, 2nd, 3rd and 
4th). Percentage change in 1st to 4th order vessel caliber 
and visible vessel number during infusions of ACh and 
ACh stimulation during blockade of prostaglandin pro-
duction and uncoupling of gap junctions from baseline.
Tissue preparation and Western blot analysis
Myocardial protein samples were homogenized in ice-
cold lysis buffer containing: 150 mM NaCl, 25 mM Tris–
HCl (pH 7.5), 5 mM  MgCl2 (pH 8.0) and 5% glycerol, 1% 
Triton X-100, complete EDTA free protease inhibitor 
cocktail (Roche, Indianapolis, USA). Myocardial proteins 
Baseline Acetylcholine
*
*
*
**
*
+/+ Veh
+/+ LIRA
*
*
* *
*
fa/fa Veh
fa/fa LIRA
vehicle ACh Indomethacin Carbenoxolone ACh
Cyclooxygenase blockade
Gap juncon blockade
5 min 5 min 10 min 10 min 5 min
Imaging
ba
c d
Fig. 1 Representative synchrotron angiograms of the coronary vasculature in Zucker rats after 8 weeks on a high-salt diet. a Images during 
baseline, infusions of acetylcholine (ACh). b Acute infusion protocol during coronary vasculature imaging. c Vessel internal diameter categorized by 
branching order during baseline ringer’s lactate infusion. d Visualized vessel number during baseline. Calibration wire (yellow arrow) = 50 μm. The 
data are shown as the mean ± SEM; N = 5–6 rats per group. The significance of group differences was determined by ANOVA for factors of genotype 
(G), drug treatment (T) and their interaction (I)
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were separated by SDS–PAGE, 30–50 µg of protein was 
loaded on 10% sodium dodecyl sulfate–polyacrylamide 
gels (Bio-Rad Laboratories, CA, USA), and subsequently 
transferred to polyvinylidene fluoride membrane. These 
membranes were then blocked for 1 h with blocking one 
and phospho-blocking one (Nacali tesque Inc, Kyoto, 
Japan) at room temperature. The following primary 
antibodies were used to quantify the myocardial pro-
tein expression levels: anti-CD-68 (1:1000, ab-31630), 
anti-GLP-1R (1:1000, sc-390773), anti-nitrotyrosine 
(NT, 1:1000, sc-32757), anti-nuclear factor (NF) kappa B 
(NF-κB, 1:1000, sc-7386), atrial natriuretic peptide (ANP, 
1:1000, ab-91250), osteopontin (OPN, 1:1000, sc-21742), 
transforming growth factor-β1 (TGF-β1, 1:1000, sc-146), 
endothelin-1 (ET-1, 1:1000, ab-2786), total eNOS 
(1:1000, sc-376751), interleukin (IL)-1β (1:1000, sc-7884) 
and β-actin (1:1000, sc-47778) (Santa Cruz Biotechnol-
ogy (sc), CA, USA; Abcam Laboratory (ab), MA, USA). 
Specific antibody binding was revealed using appropriate 
secondary antibodies (1:10,000; #7076S; Goat anti-rabbit 
IgG; #7074S; Goat anti-mouse IgG, Cell Signaling Tech-
nology, Inc. MA, USA) coupled to peroxidase and with 
the Clarity Western ECL Substrate (#1705061; Bio-Rad 
Laboratories, CA, USA). Chemiluminescence signals 
were visualized using an Amersham Imaging System 
(AI-680, GE Healthcare Life Sciences, PA, USA) and 
were quantified using β-actin signal as a protein loading 
control.
Quantitative real‑time PCR
Myocardial tissue was homogenized in TRIZOL rea-
gent (QIAGEN, CA, USA), and total RNA was extracted, 
and DNase were treated while purification (RNeasy 
Mini Purification Kit, RNase-Free DNase Set, QIA-
GEN, CA, USA). Reverse transcription was per-
formed using the High-Capacity cDNA synthesis kit 
(#4368814, Thermo Fisher Scientific, CA, USA) as per 
the manufacturer’s instructions. PCR reactions were 
performed on a StepOne 7500 RT-PCR system using 
TaqMan Universal Master Mix and predesigned prim-
ers (NOX-1: Rn00586652_m1; GPx-1: Rn00577994_g1; 
Vcam-1: Rn00563627_m1; ET-1: Rn00561129_m1; eNOS: 
Rn02132634_s1; VEGF: Rn01511602_m1) obtained from 
Applied Biosystems (Applied Biosystems, Foster City, 
CA, USA). GAPDH (Rn01775763_g1) were used as nor-
malizing internal controls. All samples were measured 
in duplicate. We employed the  2−ΔΔCt method to analyze 
the genes of interest relative to GAPDH reference gene as 
described [26].
Determination of glutathione concentrations
Reduced glutathione (GSH) and oxidized glutathione 
disulphide (GSSG) levels in plasma samples were meas-
ured using enzyme immunoassay kits (Cayman Chemical 
Corp., MI, USA) as per manufacturer’s instructions.
Histology and staining
Myocardial tissue was fixed with ice-cold 4% paraformal-
dehyde for 48 h, and embedded in paraffin, and processed 
for histology as described previously [23]. Transverse 
sections were stained either with Azan-Mallory solu-
tion for evaluation of perivascular fibrosis or with hema-
toxylin–eosin solution for evaluation of cardiomyocyte 
hypertrophy. We determine it as the ratio of the area of 
fibrosis immediately surrounding the blood vessel walls 
to the total area of the vessel. Cross-sectional area (CSA) 
of cardiomyocytes were measured for 100 cardiomyo-
cytes selected per section (400×). The mean CSA of indi-
vidual rats was then pooled for group comparisons [27].
Statistical analysis
All data are presented as mean ± SEM unless otherwise 
stated. Statistical analyses were performed with Graph 
Pad Prism software (Version 5.0, La Jolla, CA, USA). 
p < 0.05 was considered statistically significant. Normality 
was assessed using the Shapiro–Wilk test. The percent-
age change in vessel ID and the mean vessel ID of each 
branching order in individual rats (N = 5–6 animals per 
group) were pooled together for group comparisons. To 
compare the means of variables among the rat treatment 
groups we used two-way analysis of variance (ANOVA) 
test. Further, to evaluate significance of differences due to 
either genotype (G, fa/fa vs. +/+) or drug treatment (T, 
LIRA vs. vehicle) and their interaction (I).
Results
Body weights (BW) and SBP
The BW of fa/fa rats were higher than those of +/+ rats 
thought out the study. There were no significant BW 
differences in vehicle or LIRA treated groups (data not 
shown). SBP was modestly elevated in fa/fa rats (geno-
type p = 0.018) in comparison to the +/+ rats, however, 
LIRA did not significantly salter SBP (Table 1).
LIRA effect on renal function and glycemic profile
Urinary albumin, albumin-creatinine ratio, and serum 
albumin values were significantly different between the 
fa/fa and +/+ rats (genotype p < 0.0001, Table  1). These 
indices of renal dysfunction were significantly upregu-
lated in vehicle-treated fa/fa rats when compared to 
+/+ rats. LIRA did not consistently alter the elevated 
albumin in fa/fa rats, but there was a trend for creatinine 
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to be reduced by LIRA in fa/fa (interaction p = 0.069) and 
BUN was lowered by LIRA (Table 1). GFR was impaired 
in vehicle-treated fa/fa rats (genotype p = 0.018) relative 
to +/+ rats, but was nearly normalized in LIRA-treated 
fa/fa rats (drug and interaction p < 0.0001). In contrast, 
LIRA treatment did not improve creatinine clearance in 
fa/fa LIRA rats compared to those of vehicle-treated fa/
fa rats (p = 0.433). Vehicle-treated fa/fa rats developed 
mild hyperglycemia as their BG levels were a little ele-
vated compared to those of +/+ rats (genotype p = 0.211) 
which showed prediabetic BG levels presumably due 
to the high-salt diet exposure and possibly isoflurane 
conditions during blood collection. LIRA treatment 
attenuated the increase in BG level in fa/fa rats (treat-
ment p = 0.023; Table 1).
LIRA treatment improved myocardial function
As shown in Table 2, interventricular septum thickness 
at end-diastole (IVSd) (p = 0.003) was significantly 
greater than those of +/+ rats. However, LIRA treat-
ment did not reduce interventricular thickness (treat-
ment p = 0.903) relative to vehicle-treated fa/fa rats. 
However, there was no such genotype trend observed 
in interventricular septum thickness at end-systole 
Table 1 Animal characteristics, heart mass and renal function of Zucker rats after LIRA treatment on a high-salt diet
A/C albumin creatinine ratio, BG blood glucose, BUN blood urea nitrogen, BW body weight, GFR glomerular filtration rate, HW heart weight, HW/BW ratio of heart 
weight to body weight, SBP systolic blood pressure. Age-matched +/+ Veh, lean rats treated with vehicle; +/+ LIRA, lean rats treated with LIRA (0.1 mg/kg/day); fa/fa 
Veh, obese rats treated with vehicle; fa/fa LIRA, obese rats treated with LIRA (0.1 mg/kg/day)
Parameter Group 2‑way ANOVA p value
+/+ Veh +/+ LIRA fa/fa Veh fa/fa LIRA Genotype Treatment Interaction
BW (g) 322.1 ± 5.3 324.3 ± 5.8 518.0 ± 7.6 530.4 ± 14.8 < 0.0001 0.475 0.581
BG (mg/dL) 11.7 ± 0.3 11.1 ± 0.3 13.3 ± 0.9 10.7 ± 0.6 0.211 0.023 0.148
SBP (mmHg) 125.9 ± 8.5 122.0 ± 2.9 132.6 ± 7.3 123.5 ± 3.2 0.018 0.366 0.182
HW (mg) 764.5 ± 22.9 755.1 ± 12.0 922.4 ± 49.2 898.2 ± 17.3 0.0001 0.473 0.945
HW/BW ratio 2.37 ± 0.05 2.33 ± 0.07 1.78 ± 0.09 1.69 ± 0.01 < 0.0001 0.317 0.897
GFR (mL/min) 1.57 ± 0.08 1.52 ± 0.05 0.98 ± 0.19 1.28 ± 0.05 0.018 < 0.0001 < 0.0001
Albumin (mg/L) 10.0 ± 1.2 10.1 ± 1.2 75.4 ± 11.6 67.1 ± 14.1 < 0.0001 0.665 0.653
Creatinine (mg/L) 60.0 ± 6.5 76.8 ± 4.0 25.3 ± 4.1 22.2 ± 3.2 < 0.0001 0.106 0.069
A/C ratio (mg/g) 17.7 ± 3.2 13.3 ± 1.8 327.0 ± 71.1 285.9 ± 46.1 < 0.0001 0.433 0.499
BUN (mg/dL) 13.9 ± 1.1 13.9 ± 0.6 16.7 ± 0.6 14.2 ± 0.5 0.061 0.032 0.110
Serum albumin (g/dL) 2.85 ± 0.1 2.86 ± 0.1 3.62 ± 0.2 3.64 ± 0.05 < 0.0001 0.189 0.033
Table 2 Echocardiographic parameters of Zucker rats after LIRA treatment on a high-salt diet
HR heart rate, IVSd interventricular septal thickness at end-diastole, IVSs interventricular septal thickness at end-systole, LVIDd left ventricular (LV) internal dimension 
at end-diastole, LVIDs LV internal dimension at end-systole, LVPWd LV posterior wall thickness at end-diastole, LVPWs LV posterior wall thickness at end-systole, EF 
ejection fraction, FS fractional shortening, CO cardiac output. Age-matched +/+ Veh, lean rats treated with vehicle; +/+ LIRA, lean rats treated with LIRA (0.1 mg/kg/
day); fa/fa Veh, obese rats treated with vehicle; fa/fa LIRA, obese rats treated with LIRA (0.1 mg/kg/day)
*p < 0.05 vs lean rats
Parameter Group 2‑way ANOVA p value
+/+ Veh +/+ LIRA fa/fa Veh fa/fa LIRA Genotype Treatment Interaction
HR (bpm) 435 ± 28 452 ± 42 369 ± 22 375 ± 33 < 0.0001 0.191 0.416
IVSd (mm) 1.81 ± 0.14 1.87 ± 0.08 2.35 ± 0.10 2.42 ± 0.21 0.003 0.903 0.719
IVSs (mm) 2.91 ± 0.11 3.09 ± 0.25 3.27 ± 0.13 3.08 ± 0.11 0.102 0.255 0.828
LVIDd (mm) 6.17 ± 0.10 6.21 ± 0.23 6.76 ± 0.18 6.73 ± 0.26 0.033 0.953 0.941
LVIDs (mm) 2.46 ± 0.26 2.55 ± 0.43 3.87 ± 0.41 3.42 ± 0.19 0.007 0.960 0.249
LVPWd (mm) 2.37 ± 0.21 2.27 ± 0.25 2.63 ± 0.31 2.72 ± 0.20 0.059 0.800 0.912
LVPWs (mm) 3.42 ± 0.15 3.58 ± 0.25 3.30 ± 0.15 3.33 ± 0.17 0.556 0.589 0.705
EF (%) 90.63 ± 0.99 89.70 ± 1.39 82.96 ± 1.49* 84.09 ± 2.15* 0.0007 0.688 0.272
FS (%) 63.53 ± 1.56 62.69 ± 2.22 53.49 ± 1.90* 55.17 ± 2.50* 0.0006 0.658 0.211
CO (mL/min) 9.46 ± 0.41 10.53 ± 0.71 7.91 ± 0.93 9.22 ± 0.71 0.028 0.123 0.888
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(IVSs) (genotype p = 0.102; treatment p = 0.255). Left 
ventricle (LV) posterior wall in diastole (LVPWd) (gen-
otype p = 0.059) but not LV posterior wall in systole 
(LVPWs) (genotype p = 0.556) of fa/fa were larger com-
pared to those of +/+ rats. LV internal diameter at end 
diastole (LVIDd) (genotype p = 0.033) and LV internal 
diameter at end systole (LVIDs) (genotype p = 0.007) 
in fa/fa rats were larger compared with +/+ rats. How-
ever, LIRA treatment did not reduce these dimensions 
significantly, when compared to those of vehicle-
treated rats [treatment p = 0.953 (LVIDd); p = 0.960 
(LVIDs)]. However, EF, FS and cardiac output were did 
not improved in LIRA treatment [treatment p = 0.688 
(EF); p = 0.658 (FS) and p = 0.123 (CO)] (Table 2).
Baseline vessel internal diameter and visible vessel 
number
Representative synchrotron angiograms of the coro-
nary vasculature of Zucker +/+ and fa/fa rats are 
shown during baseline and ACh infusions (Fig.  1a). 
Vessel ID in vehicle-treated +/+ rats were compara-
ble with LIRA treated +/+ rats across 1st order to 4th 
order branches of the arterial vessels. In contrast, fa/
fa rats had larger diameter 2nd order than +/+ (geno-
type p = 0.017) while 3rd order in LIRA treated fa/fa 
rats (interaction p = 0.011) (Fig. 1c). A similar number 
of 1st order arterial vessel segments were visualized in 
all groups, while more 2nd and 4th order vessels were 
observed in LIRA-treated rats (Fig.  1d) (treatment 
p = 0.041 and p = 0.003). MAP during baseline under 
anesthesia was not different between rat groups while 
mean heart rate (MHR) was slightly lower in fa/fa rats 
(Fig. 3a).
LIRA treatment improved vessel responses 
to endothelium‑dependent ACh stimulation
ACh stimulation evoked a greater increase in vessel ID of 
LIRA treated rats across all branching orders but the 2nd 
order (treatment 1st—p = 0.031; 2nd—p = 0.477; 3rd—
p = 0.031; 4th—p = 0.0001), that was significantly greater 
than vehicle-treated rats, which generally did not show 
dilation in the 4th order branching vessels (Fig. 2a). How-
ever, the changes in visualized vessel number from large 
arteries to arterioles were minor and inconsistent, with a 
tendency to be slightly more visualized in LIRA treated 
rats (Fig. 2a, d). Thus, LIRA treatment primarily restored 
the dilatory response to ACh in the microvessels of fa/fa 
rats. There was a trend toward a larger decrease in MAP 
in fa/fa rats in response to ACh compare with +/+ rats 
(genotype p = 0.074; Fig. 3b). However, LIRA treated rats 
did not differ significantly in the size of the MAP change 
from vehicle-treated rats. Hence the increased dilator 
Fig. 2 LIRA treatment improved the capacity to increase perfused segments by NO-mediated dilation in Zucker fa/fa and +/+ rats after 8 weeks 
on a high-salt diet. a–d Percentage change in 1st to 4th order vessel caliber and visible vessel number during infusions of ACh and ACh stimulation 
during blockade of prostaglandin production and uncoupling of gap junctions from baseline. Mean ± SEM. The significance of group differences 
was determined by ANOVA for factors of genotype (G), drug treatment (T) and their interaction (I)
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ACh response in LIRA treated rats was not due to a dif-
ference in arterial pressure change.
LIRA treatment improved vessel response 
during prostaglandin and gap junction blockade 
and subsequent ACh stimulation
Blockade of COX and gap junctions had little influence 
on the calibre of large to medium sized vessels in the 1st 
to 3rd order branches, but was increased significantly 
in 4th order branches of LIRA treated rats (treatment 
p = 0.001; Fig. 2b). The reduction in visualized number of 
large arteries (> 300 µm class) during blockade was par-
tially alleviated by LIRA treatment mainly in the +/+ rats 
(treatment p = 0.045) (Fig.  2e). Notably, ACh-mediated 
vasodilation post blockade was of a similar magnitude 
to ACh stimulation prior to blockade in 2nd to 4th order 
branches in LIRA treated rats (Fig.  2c). Paradoxically, 
there was a small increase in the number of visualized 
large arteries > 300  µm in both fa/fa rat groups, a trend 
for a reduction in small arteries (100–200 μm class), oth-
erwise there was little change in the number of visualized 
microvessels across all groups (Fig. 2f ). Hence, transmis-
sion of endothelium-dependent radial dilation (calibre 
increase) to more distal resistance coronary vascular 
segments that were consistently visible from the base-
line was little affected by blockade of smooth muscle gap 
junctions in the LIRA treated rats but impaired in vehicle 
treated lean and obese rats.
LIRA treatment suppressed the early stages of myocardial 
inflammation
Compared with +/+ rats, protein expressions of CD-68, 
NF-κB, IL-1β and TGF-β1 were upregulated in vehi-
cle-treated fa/fa rats (genotype p < 0.05; Fig.  4). LIRA 
treatment significantly decreased expression of CD-68 
(treatment p < 0.001), NF-κB (treatment p = 0.038) 
tended to decrease and IL-1β (treatment p = 0.075) and 
a significant genotype-drug interaction (p = 0.009) indi-
cated TGF-β1 protein expression was only attenuated 
in the fa/fa rats by LIRA treatment (Fig. 4a–d). In addi-
tion, mRNA levels of Vcam-1 showed a strong trend to 
be increased (genotype p = 0.06) in fa/fa rats (Fig.  4f ). 
Hence, LIRA treatment reduced expression of the master 
regulator NF-κB and induction of downstream inflam-
matory pathways.
LIRA treatment reduced myocardial oxidative stress 
but not systemic oxidized glutathione levels
Compared with +/+ rats, NT protein expression was 
upregulated in fa/fa rats (genotype p = 0.003), but more 
attenuated by LIRA treatment (interaction p = 0.007) in 
the fa/fa rats (Fig. 5a, b). In addition, there was a strong 
trend for mRNA levels of Nox-1 to be increased (geno-
type p = 0.056) in fa/fa rats, and reduced by LIRA (treat-
ment p = 0.030) (Fig.  5c), Gpx-1 mRNA expression 
showed no significant differences between rat groups 
(Fig. 5d).
Reduced GSH plasma concentration was not different 
between the vehicle treated +/+ and fa/fa rats (Fig. 5e). 
Importantly, the concentration of oxidized GSSG lev-
els was elevated in fa/fa rats in comparison to +/+ rats 
(genotype p = 0.010), but LIRA treatment did not con-
sistently reduce this level (treatment p = 0.818; Fig.  5f ). 
Consequently, there was no difference in GSH/GSSG 
ratio (Fig. 5g).
Fig. 3 Mean arterial pressure (MAP) and mean heart rate (MHR) and their change during the acute infusion. a Change in MAP and change in MHR 
during baseline and b, c infusions of ACh, indomethacin + carbenoxolone (blockade) and post-blockade + ACh relative to vehicle Ringer’s lactate 
solution (baseline). Mean ± SEM. N = 5–6 rats per group. The significance of group differences was determined by 2-way ANOVA for factors of 
genotype (G) and drug treatment (T) and their interaction (I)
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Fig. 4 The effects of LIRA treatment on expression of CD-68, NF-κB, TGF-β1 and IL-1β in the left ventricle. a Protein expression levels of CD-68, 
NF-κB, TGF-β1 and IL-1β detected by Western blotting. β-actin was used as an internal control. Bands are representative of four separate 
experiments. b–e Relative density values of CD-68, NF-κB, TGF-β1 and IL-1β. f mRNA expression of Vcam-1 in Zucker rat myocardium. GAPDH gene 
was used as an internal control. The ΔΔcT values are shown as the mean ± SEM. N = 5–6 rats per group. The significance of group differences was 
determined by ANOVA for factors of genotype (G), drug treatment (T) and their interaction term (I)
NT
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Fig. 5 The effects of LIRA treatment on nitrosative, oxidative stress marker and anti-oxidant levels. a Protein expression levels of NT in left ventricle 
detected by Western blotting. β-actin was used as an internal control. Bands are representative of two separate experiments. b Relative density 
values of NT. c, d mRNA expressions of NOX-1 and Gpx-1 in Zucker rat myocardium. GAPDH gene was used as an internal control. The ΔΔcT 
values are shown as the mean ± SEM. Effects of LIRA on Reduced GSH (e), oxidized GSSG (f), and GSH/GSSG ratio (g). N = 5–6 rats per group. The 
significance of group differences was determined by ANOVA for factors of genotype (G), drug treatment (T) and their interaction term (I)
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LIRA treatment effects on ET‑1/NO signaling pathways 
and GLP‑1R expression
The profibrotic and vasoconstrictor factor ET-1 was ele-
vated at both mRNA (genotype p = 0.005) and protein 
(genotype p = 0.048) levels in fa/fa rats, while eNOS and 
VEGF mRNA expression levels did not differ between 
+/+ and fa/fa rats (Fig. 6a–c, g). At the protein level total 
eNOS expression was greater in fa/fa rats than +/+ rats 
(genotype p = 0.018), but this was not significantly 
altered by LIRA (Fig. 6d, f ). While VEGF mRNA tended 
to be increased by LIRA (treatment p = 0.08), VEGF 
protein expression was unexpectedly suppressed in the 
+/+ and increased in fa/fa relative to vehicle counter-
parts (treatment p = 0.007; interaction p = 0.018; Fig. 6a, 
d–e). Although myocardial GLP-1R protein expression 
appears to be mildly depressed in vehicle-treated fa/fa 
rats there was no significant difference between geno-
types (p = 0.465; Fig. 6d, h).
LIRA treatment partially attenuated perivascular fibrosis 
and myocardial remodeling markers
Azan-Mallory staining revealed that fibrosis in perivas-
cular regions of the myocardium was increased signifi-
cantly in fa/fa rats compared with +/+ rats (genotype 
p = 0.0001), but this increase in perivascular fibrosis was 
only partially attenuated in LIRA treated fa/fa rats com-
pared with vehicle-treated fa/fa rats as the drug treat-
ment was not significant, but the interaction term was 
(p = 0.033) (Fig.  7a, b). Nevertheless, protein levels of 
OPN in the LV were significantly greater in fa/fa rats 
than in +/+ rats (genotype p = 0.004) and this expression 
was normalized by LIRA treatment (treatment p = 0.007; 
interaction p = 0.003; Fig. 7c).
LIRA treatment improved myocardial hypertrophy
Compared with +/+ rats, fa/fa rats showed marked myo-
cardial hypertrophy including increased HW and car-
diomyocyte cross sectional area (genotype p = 0.0001) 
(Table  1; Fig.  8a, b). LIRA treated fa/fa rats exhibited 
less myocardial hypertrophy characterized by decreased 
cardiomyocyte cross sectional area (treatment p = 0.003, 
interaction p = 0.005), when compared with those of 
vehicle-treated fa/fa rats and +/+ rats, but this did not 
alter heart mass or HW/BW relative to the vehicle-
treated fa/fa rats (Table  1; Fig.  8a, b). Paralleling the 
difference in heart mass and cardiomyocyte cross sec-
tional area, myocardial protein levels of ANP in fa/fa rats 
were elevated compared with the +/+ rats (genotype 
p = 0.0001). However, LIRA treatment did not attenuate 
ANP expression significantly (Fig. 8c).
Discussion
Previous studies showed that a high  Na+ diet was closely 
associated with hypertension, insulin resistance, sys-
temic inflammation and oxidative stress, which thereby 
increased the incidence of cardiovascular events [28, 29]. 
ET-1
VEGF
eNOS3
β-acn
+/+ Veh +/+ LIRA fa/fa Veh fa/fa LIRA
GLP-1R
a b c d
e f g h
Fig. 6 Changes in mRNA abundance of genes related to NO-signaling pathway. a–c mRNA expressions of VEGF, eNOS and ET-1 in Zucker rat 
myocardium. GAPDH gene was used as an internal control. The ΔΔcT values are shown as the mean ± SEM. d–h The effects of LIRA treatment on 
expression of VEGF, total-eNOS, ET-1 and GLP-1R in the left ventricle. d Protein expression levels of VEGF, total-eNOS, ET-1 and GLP-1R detected by 
Western blotting. β-actin was used as an internal control. Bands are representative of five separate experiments. e–h Relative density values of VEGF, 
total-eNOS, ET-1 and GLP-1R. N = 5–6 rats per group. The significance of group differences was determined by ANOVA for factors of genotype (G), 
drug treatment (T) and their interaction term (I)
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OPN
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a
Fig. 7 Azan-Mallory staining for perivascular collagen expression. a Azan-Mallory stained myocardial sections from a vehicle-treated +/+ and 
LIRA-treated +/+ rats showing low levels of collagen deposition (blue fibrils); broad adventitial ring of strong blue fibrotic tissue reactivity in a 
vehicle-treated fa/fa rats; LIRA-treated fa/fa rats showing moderate blue fibrous tissue positivity around a coronary artery. Scale bar are 20 µm. b 
Quantification of perivascular fibrosis (%). c Protein expression levels of OPN detected by Western blotting. β-actin was used as an internal control. 
Bands are representative of two separate experiments. Relative density values of OPN, data are shown as the mean ± SEM, N = 5–6 rats per group. 
The significance of group differences was determined by ANOVA for factors of genotype (G), drug treatment (T) and their interaction term (I)
+/+ Veh +/+ LIRA
fa/fa Veh fa/fa LIRA
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Fig. 8 a Hematoxylin and eosin stained sections of myocardium illustrating cardiomyocytes in cross-section (×400). Scale bars are 20 µm. b Bar 
graph showing quantitative analysis of cross -sectional area of cardiomyocytes. c The effects of LIRA treatment on expression of ANP in left ventricle. 
c Protein expression levels of ANP detected by Western blotting. β-actin was used as an internal control. Bands are representative of two separate 
experiments. Relative density values of ANP, data are shown as the mean ± SEM, N = 5–6 rats per group. The significance of group differences was 
determined by ANOVA for factors of genotype (G), drug treatment (T) and their interaction term (I)
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In the present study, we investigated whether LIRA treat-
ment improved endothelial vasodilator function across 
the coronary macro and microcirculations and if it pre-
vented cardiac remodeling in a rat model of metabolic 
syndrome exacerbated by chronic exposure to a high  Na+ 
diet. Herein, we showed that LIRA treatment improved 
NO-mediated dilation in the coronary small arterial and 
arteriolar vessels, while reducing myocardial ET-1 pro-
tein expression in Zucker obese rats. Furthermore, LIRA 
treatment normalized cardiomyocyte cross sectional area 
but only partially reduced the development of perivascu-
lar fibrosis in association with reduced expression of pro-
tein markers of remodeling, including OPN and TGF-β1. 
Taken together, these results suggest that LIRA treatment 
greatly attenuated the progression of coronary dysfunc-
tion, partially though decreased nitrosative stress and 
ET-1 production and in part by improving endothelium 
dependent NO-mediated dilation in small arteries and 
arterioles.
The integrity and function of the endothelium is critical 
for the tonic regulation of blood flow, primarily through 
the release of vasoconstrictor and vasodilator factors 
that alter the calibre of vessels through their actions on 
underlying smooth muscle that determines local vascular 
tone in each segment. Endothelial dysfunction is an early 
sign of coronary vascular disease and impaired endothe-
lium-dependent relaxation to vasodilator agonists such 
as ACh is a characteristic clinical feature of endothelial 
dysfunction that has also been observed in both conduit 
and resistance arteries of experimental models of diabe-
tes and hypertension [30–32]. Endothelial dysfunction is 
often triggered by a reduced protein expression of eNOS 
and impaired eNOS phosphorylation at the serine 1177 
residue, decreased availability of eNOS substrate and or 
co-factors, all of which contribute to decrease NO bio-
availability. In the present study, we showed that LIRA 
improved ACh-mediated vasodilation I small artery and 
arterioles (< 150  μm diameter) in rats with metabolic 
syndrome that was exacerbated by chronic exposure to a 
high-salt diet (Figs.  1a and 2a, d). Since the ACh-medi-
ated dilatory response was of similar magnitude in the 
LIRA rats before and after blockade of dilatory prosta-
glandins we reason that this response primarily involves 
NO release and to some extend EDHF. Importantly, our 
assays of myocardial protein expression also support the 
suggestion that LIRA prevented the decline of NO and 
EDHF in the microvessels through increased eNOS and 
VEGF protein and decreased ET-1 protein (Fig. 6). These 
results suggest that LIRA treatment improved the capac-
ity for dilation of micro vessels and hence, improved 
myocardial perfusion by restoring the balance of tonic 
ET-1/NO production. Similarly, we showed utilizing 
the same rat model that improvement in endothelium 
mediated NO-dependent dilation extends to small arter-
ies and arterioles of the renal circulation [21]. In support 
of these studies, it has also been established that LIRA 
increases NO-bioavailability in the vasculature in other 
disease states including arterial stenosis [33]. Further, 
Aung et  al. [34] recently showed that local delivery of 
LIRA increased skin microvascular perfusion in diabetic 
subjects and increased supernatant nitrate concentra-
tion and eNOS phosphorylation in human microvascu-
lar endothelial cell (HCMEC/D3 cell line) culture. Taken 
together, these findings suggest that it is reasonable to 
conclude that the improvement in coronary microvas-
cular perfusion that we observed in LIRA treated obese 
Zucker rats is in part due to increased coronary NO 
production.
Multiple experimental studies have demonstrated that 
GLP-1 agonist treatment has anti-inflammatory effects 
on endothelial cells and monocytes through inhibition 
of inflammatory cascades involving vascular cell adhe-
sion molecules and intracellular adhesion molecules 
[35–37]. In addition, a recent clinical study suggest 
that LIRA treatment decreases endoplasmic reticulum 
stress in endothelial cells and restores insulin-mediated 
endothelial NO production in patients with T2DM [38]. 
In experimental diabetic animal model, LIRA treatment 
suppressed PCSK9 expression in HepG2 cells through 
HNF1α-dependent mechanism and decreased LDLR 
[39]. Further, db/db mice fed with high fat diet improved 
hepatic lipid accumulation by promoting reversal of 
cholesterol transport [40]. In our model of metabolic 
syndrome, Vcam-1 mRNA expression showed a strong 
trend to be reduced by LIRA in the kidney [21] but not 
in the myocardium [13]. On the other hand, markers of 
macrophage infiltration (CD68 protein expression and 
CD+ cell density in sections) suggest that LIRA greatly 
suppressed macrophage infiltration in both the heart 
and kidney in our studies. Furthermore, there was a 
strong trend for the somewhat elevated levels of the 
early potent inducer of the inflammatory cascade IL-1β 
to be suppressed by LIRA in obese rats. In line with this 
study, others have shown that LIRA treatment improves 
endothelial function and cardiac function through sup-
pression of oxidative stress and inflammation [41, 42].
Oxidative stress refers to the imbalance between over-
whelming oxidative processes and the depressed activity 
of anti-oxidant pathways resulting in excess accumu-
lation of reactive oxygen species (ROS) and reactive 
nitrogen  species in  vivo, causing the oxidation of pro-
teins [5, 43]. Oxidative stress damages the endothelium 
and impairs production of vasodilators such as NO as 
a result of oxidation of co-factor tetrahydrobiopterin, 
while increasing vasoconstrictor factors. Importantly, 
others have already shown that LIRA and other GLP-1 
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agonists reduce oxidative stress in diabetic rats and 
T2DM patients [17, 20, 44, 45]. However, in this study 
we found only small improvements in our assessment of 
oxidative stress and nitrosative stress imbalance. Nota-
bly, we observed a significant reduction in NT, while 
Nox1 gene transcription was also reduced (Figs.  4a, 
b and 5a–c). These findings suggest that nitrosative 
stress at least was reduced along with monocyte/mac-
rophage infiltration of the myocardium, which would be 
expected to reduce reactive nitrogen species generation 
in the matrix. However, LIRA did little in this setting of 
metabolic syndrome combined with a high  Na+ diet to 
reduce the overall redox imbalance. There was no sig-
nificant improvement at this LIRA dose in the reduced 
GSH form of and no attenuation of GSSG accumulation 
(Fig.  5e–g). Further, Gpx-1 transcription was not sig-
nificantly altered. The lack of an effect of LIRA on ROS 
generation might therefore be related to the low dose 
regime.
Previous studies have suggested that TGF-β plays a 
major role in the development of hypertension [8, 46]. 
High dietary salt intake is a potent stimulus for the vas-
cular production of TGF-β, which increased the NOX-4 
in the endothelium and thereby decreased the NO bio-
availability due to the increased ROS in the vascular 
wall leading to increased vascular tone [7]. In the cur-
rent study, no significant effect of LIRA on SBP was 
detected. However, in our hands, LIRA significantly 
lowered SBP in our previous study with the same rat 
model [21]. In both studies the LIRA normalized the 
impairment of renal function to a similar extent. Oxi-
dative stress is a driving factor in myocardial hyper-
trophy evoked by exposure to a high-salt diet [47, 48]. 
Another group has reported that LIRA administra-
tion diminished myocardial fibrosis and myocardial 
hypertrophy through the downregulation of TGF-β 
expression in obese diabetic rats [46, 49]. However, the 
current study clearly demonstrates that while this dose 
of LIRA prevents cardiomyocyte enlargement by inhib-
iting ET-1, OPN and TGF-β signaling (Figs. 7 and 8), it 
was not sufficient to normalize heart mass at the end 
of the treatment period in these young adult male rats 
with metabolic syndrome. We cannot determine from 
these findings whether the latter was due to ongoing 
excess oxidative stress, the hearts were already hyper-
trophied at the start of treatment (8  weeks of age), or 
the combined influence of these factors. Possibly for 
the same reasoning, perivascular fibrosis was only par-
tially reduced by our LIRA dose regime in these young 
adult rats.
Conclusion
Our results demonstrate that high-salt diet feeding com-
bined with metabolic syndrome evoked impairment of 
the coronary microvessel vasodilator function and sus-
tained GLP-1R activation with LIRA improved the capac-
ity for NO-mediated dilation to normalize the regulation 
of myocardial perfusion (Fig. 9). Importantly, LIRA treat-
ment restored endothelial function of coronary arterioles 
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Fig. 9 Proposed schematic representation for the beneficial effects of LIRA in coronary dysfunction associated with the additive effects of obesity 
and a high-salt diet. High-salt diet induced coronary dysfunction is characterized by increased RNS-production, inflammation and reduced 
NO bioavailability. LIRA treatment improved endothelial function, oxidative stress and inflammation. These effects are mediated through the 
downregulation of ET-1, TGF-β1 and upregulation of eNOS and to a variable extent VEGF
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through increasing NO-bioavailability as well as reducing 
the induction of inflammation in Zucker obese rats. It 
remains to be established if LIRA is equally protective in 
established diabetes combined with hypertension.
Study limitations
A limitation of the present work is that experiments were 
performed with a low dose of LIRA, however, based on 
recent published studies [16, 19] further studies are war-
ranted at higher doses. We predict that a higher dose 
might more completely inhibit inflammation and oxida-
tive stress than in the present study. Further, the current 
study was designed to investigate if NO bioavailability is 
altered by LIRA, however, we did not have the opportu-
nity to evaluate the potential contributions of EDHF to 
the improved regulation of coronary perfusion.
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